Home
Resources
Publications
Effects of Magnesium Citrate, Magnesium Oxide and Magnesium Sulfate Supplementation on Arterial Stiffness in Healthy Overweight Individuals: A Study Protocol for a Randomized Controlled Trial

Effects of Magnesium Citrate, Magnesium Oxide and Magnesium Sulfate Supplementation on Arterial Stiffness in Healthy Overweight Individuals: A Study Protocol for a Randomized Controlled Trial

Joëlle C Schutten, Peter J Joris, Ronald P Mensink, Richard M Danel, Frans Goorman, M Rebecca Heiner-Fokkema, Rinse K Weersma, Charlotte A Keyzer, Martin H de Borst, Stephan J L Bakker

Trials. 2019 May 28;20(1):295.

PMID: 31138315

Abstract:

Background:
Arterial stiffness is closely related to the process of atherosclerosis, an independent cardiovascular risk factor, and predictive of future cardiovascular events and mortality. Recently, we showed that magnesium citrate supplementation results in a clinically relevant improvement of arterial stiffness. It remained unclear whether the observed effect was due to magnesium or citrate, and whether other magnesium compounds may have similar effects. Therefore, we aim to study the long-term effects of magnesium citrate, magnesium oxide and magnesium sulfate on arterial stiffness. In addition, we aim to investigate possible underlying mechanisms, including changes in blood pressure and changes in gut microbiota diversity.
Methods:
In this randomized, double-blind, placebo-controlled trial, a total of 162 healthy overweight and slightly obese men and women will be recruited. During a 24-week intervention, individuals will be randomized to receive: magnesium citrate; magnesium oxide; magnesium sulfate (total daily dose of magnesium for each active treatment 450 mg); or placebo. The primary outcome of the study is arterial stiffness measured by the carotid-femoral pulse wave velocity (PWVc-f), which is the gold standard for quantifying arterial stiffness. Secondary outcomes are office blood pressure, measured by a continuous blood pressure monitoring device, and gut microbiota, measured in fecal samples. Measurements will be performed at baseline and at weeks 2, 12 and 24.
Discussion:
The present study is expected to provide evidence for the effects of different available magnesium formulations (organic and inorganic) on well-established cardiovascular risk markers, including arterial stiffness and blood pressure, as well as on the human gut microbiota. As such, the study may contribute to the primary prevention of cardiovascular disease in slightly obese, but otherwise healthy, individuals.
Trial registration:
ClinicalTrials.gov, NCT03632590 . Retrospectively registered on 15 August 2018.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1309484	Magnesium oxide		1309-48-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: